Expression of markers of epithelial-mesenchymal transition in breast cancer

Studenikina A.A.; Arkhipov S.A.; Zhurakovsky I.P.; Proskura A.V.; Autenshlyus A.I.

doi:https://doi.org/10.17116/patol20238504112

Studenikina A.A.

Novosibirsk State Medical University;
Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

ORCID: 0000-0003-3936-1316

Arkhipov S.A.

Novosibirsk State Medical University;
Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

ORCID: 0000-0002-1390-4426

Zhurakovsky I.P.

Novosibirsk State Medical University;
Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

ORCID: 0000-0003-0496-9401

Proskura A.V.

Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

ORCID: 0000-0003-2313-1591

Autenshlyus A.I.

Novosibirsk State Medical University;
Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

ORCID: 0000-0001-7180-010X

Expression of markers of epithelial-mesenchymal transition in breast cancer

Authors:

Studenikina A.A., Arkhipov S.A., Zhurakovsky I.P., Proskura A.V., Autenshlyus A.I.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2023;85(4): 12‑17

DOI: 10.17116/patol20238504112

Read: 1575 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Studenikina AA, Arkhipov SA, Zhurakovsky IP, Proskura AV, Autenshlyus AI. Expression of markers of epithelial-mesenchymal transition in breast cancer. Russian Journal of Archive of Pathology. 2023;85(4):12‑17. (In Russ.)
https://doi.org/10.17116/patol20238504112

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study of the expression of epithelial-mesenchymal transition markers in various molecular subtypes of cancer and in benign breast diseases with different risks of malignant transformation.

MATERIAL AND METHODS

An immunohistochemical study of the expression of E-cadherin, collagen II, integrin 1β, cyclin D1 was carried out in breast tissue samples: 58 with invasive breast carcinoma of no special type and 17 with benign breast diseases with a high and low risk of malignant transformation.

RESULTS

Patients with a triple negative molecular subtype are characterized by lower expression of collagen II compared with individuals with luminal A and B+ subtypes. A distinctive feature of patients with the HER2+ subtype was increased expression of cyclin D1 compared with the luminal A subtype, and in patients with the luminal B+ subtype, the expression of integrin 1β is higher than in the luminal B- and HER2+ subtypes. The expression of cyclin D1 in patients of both groups with benign diseases was lower than in all groups with invasive carcinoma, but at the same time, in patients with a low risk of malignant transformation, the expression of cyclin D1 was higher than in those with an increased risk.

CONCLUSION

The study revealed the relationship between the expression of markers and molecular subtypes of breast tumors, in addition, some patients with benign diseases were found who need further more careful monitoring and may be at risk for the development of malignancy.

Keywords:

breast cancer

molecular subtypes

benign breast diseases

epithelial-mesenchymal transition

Authors:

Studenikina A.A.

Novosibirsk State Medical University;
Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

ORCID: 0000-0003-3936-1316

Arkhipov S.A.

Novosibirsk State Medical University;
Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

ORCID: 0000-0002-1390-4426

Zhurakovsky I.P.

Novosibirsk State Medical University;
Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

ORCID: 0000-0003-0496-9401

Proskura A.V.

Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

ORCID: 0000-0003-2313-1591

Autenshlyus A.I.

Novosibirsk State Medical University;
Institute of Molecular Biology and Biophysics of Federal Research Center of Fundamental and Translational Medicine

ORCID: 0000-0001-7180-010X

Received:

24.12.2022

Accepted:

19.04.2023

Close metadata

References:

Thorat MA, Balasubramanian R. Breast cancer prevention in high-risk women. Best Pract Res Clin Obstet Gynaecol. 2020;65:18-31. https://doi.org/10.1016/j.bpobgyn.2019.11.006
Louro J, Román M, Posso M, Comerma L, Vidal C, Saladié F, Alcantara R, Sanchez M, Quintana MJ, Del Riego J, et al. Differences in breast cancer risk after benign breast disease by type of screening diagnosis. Breast. 2020;54:343-348. https://doi.org/10.1016/j.breast.2020.09.005
Román M, Louro J, Posso M, Vidal C, Bargalló X, Vázquez I, Quintana MJ, Alcántara R, Saladié F, Del Riego J, et al.; On Behalf Of The Bele And Iris Study Groups. Long-term risk of breast cancer after diagnosis of benign breast disease by screening mammography. Int J Environ Res Public Health. 2022;19(5):2625. https://doi.org/10.3390/ijerph19052625
Negro G, Aschenbrenner B, Brezar SK, Cemazar M, Coer A, Gasljevic G, Savic D, Sorokin M, Buzdin A, Callari M, et al. Molecular heterogeneity in breast carcinoma cells with increased invasive capacities. Radiol Oncol. 2020;54(1):103-118. https://doi.org/10.2478/raon-2020-0007
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181-185. https://doi.org/10.1111/his.14091
Mohd Sobri SN, Abdul Sani SF, Sabtu SN, Looi LM, Chiew SF, Pathmanathan D, Chio-Srichan S, Bradley DA. Structural studies of epithelial mesenchymal transition breast tissues. Sci Rep. 2020;10(1):1997. https://doi.org/10.1038/s41598-020-58932-5
Lüönd F, Sugiyama N, Bill R, Bornes L, Hager C, Tang F, Santacroce N, Beisel C, Ivanek R, Bürglin T, et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021;56(23):3203-3221.e11. https://doi.org/10.1016/j.devcel.2021.11.006
Savci-Heijink CD, Halfwerk H, Hooijer GKJ, Koster J, Horlings HM, Meijer SL, van de Vijver MJ. Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior. Breast Cancer Res Treat. 2019;174(3): 649-659. https://doi.org/10.1007/s10549-018-05089-5
Horne HN, Oh H, Sherman ME, Palakal M, Hewitt SM, Schmidt MK, Milne RL. E-cadherin breast tumor expression, risk factors and survival: pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Sci Rep. 2018;8(1):6574. https://doi.org/10.1038/s41598-018-23733-4
Yin HL, Wu CC, Lin CH, Chai CY, Hou MF, Chang SJ, Tsai HP, Hung WC, Pan MR, Luo CW. β1 integrin as a prognostic and predictive marker in triple-negative breast cancer. Int J Mol Sci. 2016;17(9):1432. https://doi.org/10.3390/ijms17091432
Zuo XX, Yang Y, Zhang Y, Zhang ZG, Wang XF, Shi YG. Platelets promote breast cancer cell MCF-7 metastasis by direct interaction: surface integrin α2β1-contacting-mediated activation of Wnt-β-catenin pathway. Cell Commun Signal. 2019;17(1):142. https://doi.org/10.1186/s12964-019-0464-x
Ruan Y, Chen L, Xie D, Luo T, Xu Y, Ye T, Chen X, Feng X, Wu X. Mechanisms of cell adhesion molecules in endocrine-related cancers: a concise outlook. Front Endocrinol (Lausanne). 2022;13:865436. https://doi.org/10.3389/fendo.2022.865436
Nissen NI, Karsdal M, Willumsen N. Collagens and cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology. J Exp Clin Cancer Res. 2019;38(1):115. https://doi.org/10.1186/s13046-019-1110-6
O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417-430. https://doi.org/10.1038/nrclinonc.2016.26
Bakr NM, Mahmoud MS, Nabil R, Boushnak H, Swellam M. Impact of circulating miRNA-373 on breast cancer diagnosis through targeting VEGF and cyclin D1 genes. J Genet Eng Biotechnol. 2021; 19(1):84. https://doi.org/10.1186/s43141-021-00174-7